Khan, Sajid http://orcid.org/0000-0003-1331-8846
He, Yonghan
Zhang, Xuan http://orcid.org/0000-0001-6062-6708
Yuan, Yaxia
Pu, Shaoyan
Kong, Qingpeng http://orcid.org/0000-0002-6046-4494
Zheng, Guangrong
Zhou, Daohong http://orcid.org/0000-0002-2400-6461
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA219836, R01CA242003, R01CA211963, R21CA223371)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 10 April 2020
Revised: 14 May 2020
Accepted: 18 May 2020
First Online: 31 May 2020
Compliance with ethical standards
:
: SK, YH, XZ, GZ, and DZ are inventors of two pending patent applications for use of Bcl-xL PROTACs as senolytic and antitumor agents. GZ, and DZ are co-founders of and have equity in Dialectic Therapeutics, which develops Bcl-xL PROTACs to treat cancer. The remaining authors declare no conflict of interests.